P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib
Authors
Keywords
-
Journal
ACTA PHARMACOLOGICA SINICA
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-04-13
DOI
10.1038/s41401-021-00643-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency
- (2018) Chaoyang Sun et al. CANCER CELL
- BET inhibition overcomes receptor tyrosine kinase-mediated cetuximab resistance in HNSCC
- (2018) Brandon Leonard et al. CANCER RESEARCH
- Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas
- (2018) Soham D. Puvvada et al. Clinical Lymphoma Myeloma & Leukemia
- Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer
- (2018) Aishwarya Pawar et al. Cell Reports
- A dynamic N6-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors
- (2018) Fei Yan et al. CELL RESEARCH
- Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
- (2017) Loren M. Lasko et al. NATURE
- HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma
- (2016) Caron Jacobson et al. BLOOD
- The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways
- (2016) Igor Hrgovic et al. BMC CANCER
- HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC- Driven Medulloblastoma
- (2016) Yanxin Pei et al. CANCER CELL
- Molecular Pathways: The eIF4F Translation Initiation Complex—New Opportunities for Cancer Treatment
- (2016) Hélène Malka-Mahieu et al. CLINICAL CANCER RESEARCH
- BET and BRAF inhibitors act synergistically againstBRAF-mutant melanoma
- (2016) Luca Paoluzzi et al. Cancer Medicine
- CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
- (2014) Sadhna R. Vora et al. CANCER CELL
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
- (2014) Irfan A. Asangani et al. NATURE
- featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
- (2013) Y. Liao et al. BIOINFORMATICS
- RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer
- (2013) Violeta Serra et al. JOURNAL OF CLINICAL INVESTIGATION
- A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
- (2013) Cory M. Johannessen et al. NATURE
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- Molecular pathogenesis of mantle cell lymphoma
- (2012) Pedro Jares et al. JOURNAL OF CLINICAL INVESTIGATION
- PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies HarboringPIK3CAMutations
- (2012) Filip Janku et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
- (2011) P N Munster et al. BRITISH JOURNAL OF CANCER
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
- (2011) F. Janku et al. MOLECULAR CANCER THERAPEUTICS
- PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
- (2011) V Serra et al. ONCOGENE
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation
- (2010) Qihuang Jin et al. EMBO JOURNAL
- Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
- (2010) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL INVESTIGATION
- Mantle cell lymphoma: state-of-the-art management and future perspective
- (2010) Oliver Weigert et al. LEUKEMIA & LYMPHOMA
- How I treat mantle cell lymphoma
- (2009) M. Ghielmini et al. BLOOD
- Genome-wide Mapping of HATs and HDACs Reveals Distinct Functions in Active and Inactive Genes
- (2009) Zhibin Wang et al. CELL
- Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma
- (2008) J. Dal Col et al. BLOOD
- A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
- (2007) E. Hoster et al. BLOOD
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started